NO20051664L - Behandling av demens og Parkinsons sykdom - Google Patents
Behandling av demens og Parkinsons sykdomInfo
- Publication number
- NO20051664L NO20051664L NO20051664A NO20051664A NO20051664L NO 20051664 L NO20051664 L NO 20051664L NO 20051664 A NO20051664 A NO 20051664A NO 20051664 A NO20051664 A NO 20051664A NO 20051664 L NO20051664 L NO 20051664L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- parkinson
- dementia
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Fremgangsmåter for å forebygge eller forsinke degenerasjon av nevroner og/eller fremgangsmåter for behandling av Aizheimers- eller Parkinsons sykdom, omfattende administrering av en terapeutisk effektiv mengde av brimonidin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41703102P | 2002-10-08 | 2002-10-08 | |
PCT/US2003/031842 WO2004032934A1 (en) | 2002-10-08 | 2003-10-07 | Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20051664L true NO20051664L (no) | 2005-05-31 |
Family
ID=32093952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20051664A NO20051664L (no) | 2002-10-08 | 2005-04-04 | Behandling av demens og Parkinsons sykdom |
Country Status (20)
Country | Link |
---|---|
US (1) | US20040116436A1 (no) |
EP (1) | EP1549314B1 (no) |
JP (1) | JP2006504741A (no) |
KR (1) | KR20050056235A (no) |
CN (1) | CN100370988C (no) |
AT (1) | ATE380551T1 (no) |
AU (2) | AU2003279874A1 (no) |
BR (1) | BR0314541A (no) |
CA (1) | CA2501348A1 (no) |
DE (1) | DE60318081T2 (no) |
ES (1) | ES2297233T3 (no) |
HK (1) | HK1080408B (no) |
IL (1) | IL167848A (no) |
MX (1) | MXPA05003665A (no) |
NO (1) | NO20051664L (no) |
NZ (1) | NZ539329A (no) |
PL (1) | PL376347A1 (no) |
RU (1) | RU2332218C2 (no) |
WO (1) | WO2004032934A1 (no) |
ZA (1) | ZA200502745B (no) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7512436B2 (en) * | 2004-02-12 | 2009-03-31 | The Regents Of The University Of Michigan | Method of evaluating metabolism of the eye |
US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
US20100298305A1 (en) * | 2008-11-26 | 2010-11-25 | The United States Government, As Represented By The Department Of Veterans Affairs | Tizanidine for the treatment of post-traumatic stress disorder and nightmares |
DE102009043750A1 (de) * | 2009-09-30 | 2011-08-04 | Carl Zeiss Meditec AG, 07745 | Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge |
US10022341B2 (en) * | 2014-12-02 | 2018-07-17 | Yale University | Methods of preventing neurodegeneration of association cortex in a mammal |
RU2680526C1 (ru) * | 2016-07-05 | 2019-02-22 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота |
CA3031528A1 (en) * | 2016-08-01 | 2018-02-08 | Cognoptix, Inc. | System and method for detecting tau protein in ocular tissue |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029792A (en) * | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
US5210076A (en) * | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
ATE258067T1 (de) * | 1995-05-26 | 2004-02-15 | Pfizer | Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält |
US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
US6329369B1 (en) * | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
NZ504667A (en) * | 1997-12-04 | 2003-03-28 | Allergan Sales Inc | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
US6313172B1 (en) * | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
NZ521185A (en) * | 2000-07-14 | 2005-02-25 | Allergan Inc | Compositions containing alpha-2-adrenergic agonist components |
-
2003
- 2003-10-07 KR KR1020057006115A patent/KR20050056235A/ko not_active Application Discontinuation
- 2003-10-07 AT AT03773199T patent/ATE380551T1/de not_active IP Right Cessation
- 2003-10-07 WO PCT/US2003/031842 patent/WO2004032934A1/en active IP Right Grant
- 2003-10-07 MX MXPA05003665A patent/MXPA05003665A/es active IP Right Grant
- 2003-10-07 AU AU2003279874A patent/AU2003279874A1/en not_active Abandoned
- 2003-10-07 DE DE60318081T patent/DE60318081T2/de not_active Expired - Lifetime
- 2003-10-07 CN CNB2003801011164A patent/CN100370988C/zh not_active Expired - Fee Related
- 2003-10-07 BR BR0314541-7A patent/BR0314541A/pt not_active IP Right Cessation
- 2003-10-07 CA CA002501348A patent/CA2501348A1/en not_active Abandoned
- 2003-10-07 RU RU2005114505/14A patent/RU2332218C2/ru not_active IP Right Cessation
- 2003-10-07 EP EP03773199A patent/EP1549314B1/en not_active Expired - Lifetime
- 2003-10-07 NZ NZ539329A patent/NZ539329A/en not_active IP Right Cessation
- 2003-10-07 JP JP2004543508A patent/JP2006504741A/ja active Pending
- 2003-10-07 US US10/680,996 patent/US20040116436A1/en not_active Abandoned
- 2003-10-07 ES ES03773199T patent/ES2297233T3/es not_active Expired - Lifetime
- 2003-10-07 PL PL03376347A patent/PL376347A1/xx not_active Application Discontinuation
-
2005
- 2005-04-04 IL IL167848A patent/IL167848A/en not_active IP Right Cessation
- 2005-04-04 NO NO20051664A patent/NO20051664L/no not_active Application Discontinuation
- 2005-04-05 ZA ZA200502745A patent/ZA200502745B/en unknown
-
2006
- 2006-01-04 HK HK06100172.4A patent/HK1080408B/zh not_active IP Right Cessation
-
2010
- 2010-02-26 AU AU2010200730A patent/AU2010200730A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL376347A1 (en) | 2005-12-27 |
NZ539329A (en) | 2007-11-30 |
BR0314541A (pt) | 2005-07-26 |
DE60318081T2 (de) | 2008-11-06 |
AU2003279874A1 (en) | 2004-05-04 |
HK1080408B (zh) | 2008-08-08 |
ES2297233T3 (es) | 2008-05-01 |
CN1703222A (zh) | 2005-11-30 |
EP1549314B1 (en) | 2007-12-12 |
CN100370988C (zh) | 2008-02-27 |
JP2006504741A (ja) | 2006-02-09 |
ATE380551T1 (de) | 2007-12-15 |
IL167848A (en) | 2010-11-30 |
RU2005114505A (ru) | 2005-10-27 |
CA2501348A1 (en) | 2004-04-22 |
WO2004032934A1 (en) | 2004-04-22 |
RU2332218C2 (ru) | 2008-08-27 |
DE60318081D1 (de) | 2008-01-24 |
ZA200502745B (en) | 2006-07-26 |
EP1549314A1 (en) | 2005-07-06 |
HK1080408A1 (en) | 2006-04-28 |
KR20050056235A (ko) | 2005-06-14 |
MXPA05003665A (es) | 2005-06-08 |
AU2010200730A1 (en) | 2010-03-18 |
US20040116436A1 (en) | 2004-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60132777D1 (de) | Benzothiazolderivate zur behandlung von alzheimer und parkinson | |
NO20052760D0 (no) | Fremgangsmate for behandling av kreft og beslektede fremgangsmater. | |
NO20051664L (no) | Behandling av demens og Parkinsons sykdom | |
NO20004803L (no) | Smilagening og anzurogenin for behandling av Alzheimers sykdom | |
NO20034056D0 (no) | Proliferative sykdommer | |
DK1292294T3 (da) | Anvendelse af mediumkæde-triglycerider til behandling og forebyggelse af Alzheimers sygdom | |
GB0223038D0 (en) | Therapeutic compounds | |
DK0721449T3 (da) | Inhibitorer af beta-amyloidproteinproduktion | |
NO20022531D0 (no) | Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer | |
DE60010702D1 (de) | Behandlung von titanerz zur herstellung von titandioxidpigmenten | |
ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
ATE354563T1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
BR0214309A (pt) | Derivados aril-1,4-pirazina substituìdos | |
MY130489A (en) | Substituted aryl 1, 4-pyrazine derivatives | |
GB0117645D0 (en) | Therapeutic stratergies for prevention and treatment of alzheimers disease | |
PT1224205E (pt) | Derivados 5-beta-sapogenina e pseudo-sapogenina e sua utilizacao no tratamento de demencia | |
NO20043085L (no) | Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet | |
ATE384699T1 (de) | 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten | |
NO20052153L (no) | Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. | |
NO20053341D0 (no) | Hindring og behandling av Alzheimers sykdom. | |
ATE427928T1 (de) | Fluorobenzamide zur behandlung von alzheimer oder seniler dementia | |
WO2004026258A3 (en) | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease | |
ATE294584T1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
DE60327335D1 (de) | Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |